Abstract
Respiratory syncytial virus (RSV) is an important cause of childhood respiratory disease as well as exacerbations of asthma. Although previous studies have demonstrated that a DNA vaccine encoding the RSV G protein can inhibit RSV replication in mouse models of RSV infection, studies have not been performed to determine whether a DNA vaccine encoding the RSV G protein can protect against RSV induced mucus expression and airway hyperresponsiveness which was the focus of this study. The DNA-G vaccine we constructed significantly inhibited RSV viral replication, mucus expression, and importantly was associated with inhibition of RSV induced airway responsiveness.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies, Viral / blood
-
Base Sequence
-
Bronchoalveolar Lavage Fluid / cytology
-
Bronchoalveolar Lavage Fluid / immunology
-
Female
-
Humans
-
Immunoglobulin G / blood
-
Interleukin-13 / metabolism
-
Mice
-
Mice, Inbred BALB C
-
Mucus / physiology
-
Plasmids / genetics
-
Respiratory Hypersensitivity / immunology
-
Respiratory Hypersensitivity / prevention & control
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / prevention & control
-
Respiratory Syncytial Viruses / genetics
-
Respiratory Syncytial Viruses / immunology*
-
Respiratory Syncytial Viruses / pathogenicity
-
Vaccines, DNA / genetics
-
Vaccines, DNA / pharmacology*
-
Viral Proteins / genetics
-
Viral Proteins / immunology*
-
Viral Vaccines / genetics
-
Viral Vaccines / pharmacology*
Substances
-
Antibodies, Viral
-
Immunoglobulin G
-
Interleukin-13
-
Vaccines, DNA
-
Viral Proteins
-
Viral Vaccines